Simponi vs Skyrizi for Ulcerative Colitis: A Patient Guide

Simponi and Skyrizi represent two different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Skyrizi (risankizumab) is an IL-23 p19-selective biologic that gained UC approval in June 2024 based on INSPIRE and COMMAND. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and safety data. This guide walks through the simponi vs skyrizi ulcerative colitis comparison.

Anti-TNF vs IL-23 p19 Mechanism

Simponi binds TNF-alpha and reduces inflammation throughout the body and in the colon. Skyrizi binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 is a central driver of Th17-mediated inflammation in UC. The golimumab vs risankizumab distinction shapes both speed of onset and the long-term safety profile. Simponi's broader TNF blockade produces rapid systemic anti-inflammatory effects. Skyrizi's selective IL-23 inhibition produces strong efficacy with a cleaner infection profile.

UC Efficacy Data

Simponi's UC efficacy rests on PURSUIT-SC (induction) and PURSUIT-M (maintenance). Skyrizi's UC efficacy rests on INSPIRE (induction) and COMMAND (maintenance). INSPIRE showed clinical remission rates of 20.3% on Skyrizi versus 6.2% on placebo at week 12, with endoscopic improvement and symptomatic remission also significantly better. COMMAND showed sustained benefit through week 52. No head-to-head trial has directly compared Simponi with Skyrizi in UC. Indirect comparisons suggest Skyrizi produces comparable or potentially stronger clinical remission rates, with particular advantage on endoscopic endpoints.

Onset of Action

Simponi produces meaningful UC response by week 6 based on PURSUIT-SC. Skyrizi's UC onset produces meaningful response by week 12 based on INSPIRE. For UC patients with severe, active symptoms who need rapid control, Simponi's faster onset is often preferred. For patients in less acute states or those weighing long-term administration and safety, Skyrizi's response trajectory is generally acceptable given the other advantages.

Safety and Infection Risk

Simponi carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Skyrizi's UC safety data from INSPIRE and COMMAND has been favorable, consistent with its broader Crohn's and psoriasis experience. Long-term data for IL-23 p19 biologics consistently shows lower rates of serious systemic infection than anti-TNFs. For simponi vs skyrizi side effects in patients with infection concerns, cancer history, or comorbidities, Skyrizi's narrower mechanism often looks more favorable. Both drugs require TB and hepatitis B screening before starting.

Administration and Dosing

Simponi for UC uses 200 mg SC at week 0, 100 mg at week 2, and then 100 mg every 4 weeks for maintenance, per Janssen's prescribing information. Simponi is all-SC throughout. Skyrizi for UC uses IV induction at weeks 0, 4, and 8 (1200 mg per infusion), followed by subcutaneous maintenance of 180 mg or 360 mg every 8 weeks. For UC patients comparing administration, Simponi is fully SC, while Skyrizi requires IV induction before transitioning to SC maintenance. Skyrizi's every-8-week maintenance cadence is less frequent than Simponi's every-4-week schedule.

Anti-TNF Experienced Patients

For patients who have failed or lost response to a prior anti-TNF, a mechanism switch to Skyrizi is supported by INSPIRE data, which included biologic-experienced UC patients. Cycling within the anti-TNF class (to Simponi from another anti-TNF) typically delivers lower response rates than changing mechanism classes. For UC patients with prior anti-TNF exposure, Skyrizi often has better expected response.

Extraintestinal Manifestations

Simponi, as an anti-TNF, covers UC-associated extraintestinal manifestations like peripheral arthritis, ankylosing spondylitis, and certain skin conditions. Skyrizi is approved for psoriasis and psoriatic arthritis through its IL-23 mechanism. For UC patients with comorbid psoriasis or psoriatic arthritis, Skyrizi may offer dual benefit. For UC patients with peripheral arthritis or ankylosing spondylitis, Simponi's TNF mechanism is often preferred.

Cost and Access

Simponi's SC formulation currently lacks widely available biosimilars in the US market. Skyrizi is also branded with no biosimilar. Insurance coverage varies by plan, and prior authorization is typically required for both drugs in UC. Manufacturer copay assistance programs exist for commercially insured patients on both drugs.

Choosing With Your GI

For a UC patient deciding between Simponi and Skyrizi, Simponi tends to win on faster onset, fully SC administration throughout, and extraintestinal manifestation coverage for peripheral arthritis and ankylosing spondylitis. Skyrizi tends to win on long-term safety, less frequent SC maintenance (every 8 weeks vs every 4 weeks), stronger endoscopic outcomes, and performance in anti-TNF experienced patients. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency, blood, and any new extraintestinal symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.